Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients

Kidney transplant recipients are at an increased risk of severe COVID-19-associated hospitalisation and death. Vaccination has been a key public health strategy to reduce disease severity and infectivity, but the effectiveness of COVID vaccines is markedly reduced in kidney transplant recipients. Ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunbridge, Matthew, Perkins, Griffith B., Singer, Julian, Salehi, Tania, Ying, Tracey, Grubor-Bauk, Branka, Barry, Simon, Sim, Beatrice, Hissaria, Pravin, Chadban, Steven J., Coates, P. Toby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477178/
https://www.ncbi.nlm.nih.gov/pubmed/36109788
http://dx.doi.org/10.1186/s13063-022-06634-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477178/
https://www.ncbi.nlm.nih.gov/pubmed/36109788
http://dx.doi.org/10.1186/s13063-022-06634-w

Ejemplares similares